Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review

Critical Reviews in Oncology/Hematology

Volumn 75, Issue 1, 2010, Pages 27-42

  Pentheroudakis, George ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

Cancer of unknown primary; Peritoneal carcinomatosis; Peritoneum; Serous papillary carcinoma

Indexed keywords

ALKYLATING AGENT; BRCA1 PROTEIN; CA 125 ANTIGEN; CELL ADHESION MOLECULE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL MEMBRANE ANTIGEN; KI 67 ANTIGEN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; ONCOPROTEIN; PACLITAXEL; PANCYTOKERATINE; PLATINUM; PROTEIN BCL 2; PROTEIN LN1; PROTEIN LN21; PROTEIN P53; PROTEIN S 100; TAXANE DERIVATIVE; TUMOR SUPPRESOR WILMS TUMOR 1; UNCLASSIFIED DRUG;

CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; GENE DELETION; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; REVIEW; SEROUS PERITONEAL PAPILLARY CARCINOMA; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; CARCINOMA, PAPILLARY; FEMALE; METABOLISM; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS;

CARCINOMA, PAPILLARY; FEMALE; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 77953808505     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.10.003     Document Type: Review

References (59)

1. Hainsworth J., Fizazi K. Treatment for patients with unknown primary cancer and favourable prognostic factors. Semin Oncol 2009, 36:44-51.
2. Resta L., Maiorano E., Zito F.A., et al. Multifocal extraovarian serous carcinoma: a histochemical and immunohistochemical study. Eur J Gynaecol Oncol 1988, 9:474-478.
3. Bloss J.D., Shu-Yuan L., Buller R.E., et al. Extraovarin peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 1993, 50:347-351.
4. Wick M.R., Mills S.E., Dehner L.P., Bollinger D.J., Fechner R.E. Serous papillary carcinomas arising from the peritoneum and ovaries. Int J Gynecol Pathol 1989, 8:179-188.
5. Schorge J.O., Miller Y.B., Qi L.G., et al. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 2000, 76:369-372.
6. Terai Y., Ueda M., Kumagai K., Ueki K., Ueki M. Tumor angiogenesis and thymidine phosphorylase expression in ovarian carcinomas including serous surface papillary adenocarcinoma of the peritoneum. Int J Gynecol Pathol 2000, 19:354-360.
7. Moll U.M., Valea F., Chumas J. Role of p53 alteration in primary peritoneal carcinoma. Int J Gynecol Pathol 1997, 16:156-162.
8. Cass I., Baldwin R.L., Fasylova E., et al. Allelotype of papillary serous peritoneal carcinomas. Gynecol Oncol 2001, 82:69-76.
9. Kowalski L.D., Kanbour A.I., Price F.V., et al. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer 1997, 79:1587-1594.
10. Halperin R., Zehavi S., Hadas E., Habler L., Bukovsky I., Schneider D. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int J Gynecol Pathol 2001, 20:341-345.
11. Chen L.M., Yamada S.D., Fu Y.S., Baldwin R.L., Karlan B.Y. Molecular similarities between primary peritoneal and primary ovarian carcinomas. Int J Gynecol Cancer 2003, 13:749-755.
12. Huang L.W., Garrett A.P., Schorge J.O., et al. Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol 2000, 114:93-99.
13. Huang L.W., Garrett A.P., Muto M.G., et al. Identification of a novel 9cM deletion unit on chromosome 6q23-24 in papillary serous carcinoma of the peritoneum. Hum Pathol 2000, 31:367-373.
14. Quezado M.M., Moskaluk C.A., Bryant B., Mills S.E., Merino M.J. Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma. Hum Pathol 1999, 30:203-207.
15. Bandera C.A., Muto M.G., Schorge J.O., Berkowitz R.S., Rubin S.C., Mok S.C. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998, 92:596-600.
16. Schorge J.O., Muto M.G., Welch W.R., et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998, 90:841-845.
17. Bloss J.D., Brady M.F., Liao S.Y., Rocereto T., Partridge E.E., Clarke-Pearson D.L. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol 2003, 89:148-154.
18. Lele S.B., Piver M.S., Matharu J., Tsukada Y. Peritoneal papillary carcinoma. Gynecol Oncol 1988, 31:315-320.
19. Mills S.E., Andersen W.A., Fechner R.E., Austin M.B. Serous surface papillary carcinoma. A clinicopathologic study of ten cases and comparison with stage III/IV ovarian serous carcinoma. Am J Surg Pathol 1988, 12:827-834.
20. Strnad C.M., Grosh W.W., Baxter J., et al. Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma. Ann Intern Med 1989, 111:213-217.
21. Dalrymple J.C., Bannatyne P., Russell P., et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer 1989, 64:110-115.
22. Fromm G.L., Gershenson D.M., Silva E.G. Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990, 75:89-95.
23. Ransom D.T., Shreyaskumar R.P., Keeney G.L., Malkasian G.D., Edmonson J.H. Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer 1990, 66:1091-1094.
24. Truong L.D., Maccato M.L., Awalt H., Cagle P.T., Schwarz M.R., Kaplan A.L. Serous surface carcinoma of the peritoneum: a clincopathologic study of 22 cases. Hum Pathol 1990, 21:99-110.
25. Killackey M.A., Davis A.R. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 1993, 51:171-174.
26. Fowler J.M., Nieberg R.K., Schooler T.A., Berek J.S. Peritoneal adenocarcinoma serous of Mullerian type: a subgroup of women presenting with peritoneal carcinomatosis. Int J Gynecol Cancer 1994, 4:43-51.
27. Zhou J., Iwasa Y., Konishi I., et al. Papillary serous carcinoma of the peritoneum in women. A clinicopathologic and immunohistochemical study. Cancer 1995, 76:429-436.
28. Baruch G.B., Sivan E., Moran O., Rizel S., Menczer J., Seidman D.S. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol 1996, 60:393-396.
29. Liapis A., Condi-Paphiti A., Pyrgiotis E., Zourlas P.A. Ovarian surface serous papillary carcinomas: a clinicopathologic study. Eur J Gynaecol Oncol 1996, 17:79-82.
30. Taus P., Petru E., Gucer F., Pickel H., Lahousen M. Primary serous papillary carcinoma of the peritoneum: a report of 18 patients. Eur J Gynaecol Oncol 1997, 18:171-172.
31. Piver M.S., Eltabakkh G.H., Hempling R., Recio F., Blumenson L. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol Oncol 1997, 67:141-146.
32. Piura B., Meirovitz M., Bartfeld M., Yanai-Inbar I., Cohen Y. Peritoneal papillary serous carcinoma: study of 15 cases and comparison with stage III-IV ovarian papillary serous carcinoma. J Surg Oncol 1998, 68:173-178.
33. Kennedy A.W., Markman M., Webster K., et al. Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum. Gynecol Oncol 1998, 71:288-290.
34. Eltabbakh G.H., Mount S.L. Lymphatic spread among women with primary peritoneal carcinoma. J Surg Oncol 2002, 81:126-131.
35. Pentheroudakis G., Briasoulis E., Karavasilis V., et al. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?. Acta Oncol 2005, 44:155-160.
36. Choi C.H., Kim T.J., Kim W.Y., et al. Papillary serous carcinoma in ovaries of normal size: A clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. Gynecol Oncol 2007, 105:762-768.
37. Zhang C., Li X.P., Cui H., Shen D., Wei L. Advanced primary peritoneal carcinoma: clinicopathologic and prognostic factor analyses. J Zhejiang Univ Sci B 2008, 9:435-440.
38. Levanon K., Crum C., Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008, 26:5284-5293.
39. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008, 9:1191-1197.
40. Piek J., Kenemans P., Verheijen R. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004, 191:718-732.
41. Spurgeon J., Cotlar A.M. Cytoreductive surgery in the management of malignant ascites form adenocarcinoma of unknown primary. Curr Surg 2005, 62:500-503.
42. Rubatt J.M., Darcy K.M., Hutson A., et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status and angiogenic marker expression: a GOG study. Gynecol Oncol 2009, 112:469-474.
43. Sasaki R., Narisawa-Saito M., Yugawa T., et al. Oncogenic transformation of human ovarian surface epithelial cells with defined cellular oncogenes. Carcinogenesis 2009, 19126650.
44. Lee Y., Park N. Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecol Oncol 2009, 112:475-480.
45. Darcy K.M., Brady W.E., McBroom J.W., et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk early stage or suboptimally-resected advanced stage epithelial ovarian cancers. A GOG study. Gynecol Oncol 2008, 111:487-495.
46. Vang R., Shih I., Salani R., Sugar E., Ayhan A., Kurman R.J. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol 2008, 32:1667-1674.
47. Lee Y., Miron A., Drapkin R., et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007, 211:26-35.
48. Tuefferd M., Couturier J., Penault-Llorca F., et al. HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One 2007, 2:e1138.
49. Steffensen K., Waldstom M., Andersen R.F., et al. Protein levels and gene expressions of the epidermal growth factor receptors HER1, HER2, HER3 and HER4 in benign and malignant epithelial ovarian tumours. Int J Oncol 2008, 33:195-204.
50. Olivier R., van Beurden M., Lubsen M.A., et al. Clinical outcome of prophylactic oophorectomy in BRCA1/2 mutation carriers and events during follow-up. Br J Cancer 2004, 90:1492-1497.
51. Wang P., Shyong W., Li Y., et al. BRCA1 mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma. Jpn J Clin Oncol 2000, 30:343-348.
52. Li S., Han H., Resnik E., Carcangiu M.L., Schwartz P.E., Yang-Feng T. Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gynecol Oncol 1993, 51:21-25.
53. Schorge J., Muto M., Lee S., et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000, 60:1361-1364.
54. Petru E., Luck H., Stuart G., Gaffney D., Millan D., Vergote I. GCIG proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol 2009, 19195765.
55. Zivanovic O., Eisenhauer E., Zhou Q., et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIc epithelial ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 2008, 108:287-292.
56. Pavlidis N., Briasoulis E., Hainsworth J., Greco F.A. Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer 2003, 39:1990-2005.
57. Pentheroudakis G., Golfinopoulos V., Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007, 43:2026-2036.
58. Pentheroudakis G., Pavlidis N. Perspectives for targeted therapies in cancer of unknown primary site. Cancer Treat Rev 2006, 32:637-644.
59. Greco F.A., Pavlidis N. Treatment for patients with unknown primary carcinoma and unfavourable prognostic factors. Semin Oncol 2009, 36:65-74.